INCY – Incyte Corporation
Float Short %
3.85
Margin Of Safety %
10
Put/Call OI Ratio
0.65
EPS Next Q Diff
0.5
EPS Last/This Y
5.93
EPS This/Next Y
1.07
Price
85.04
Target Price
82.4
Analyst Recom
2.39
Performance Q
31.82
Relative Volume
0.79
Beta
0.74
Ticker: INCY
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-28 | INCY | 70.21 | 0.58 | 0.03 | 11346 |
| 2025-07-29 | INCY | 77.4 | 0.45 | 0.41 | 13376 |
| 2025-07-30 | INCY | 77.55 | 0.47 | 0.52 | 14457 |
| 2025-07-31 | INCY | 74.9 | 0.47 | 1.49 | 14576 |
| 2025-08-01 | INCY | 75.6 | 0.49 | 0.88 | 14867 |
| 2025-08-04 | INCY | 78.06 | 0.49 | 0.07 | 14842 |
| 2025-08-05 | INCY | 77.75 | 0.49 | 0.54 | 14872 |
| 2025-08-06 | INCY | 77.65 | 0.48 | 0.09 | 14771 |
| 2025-08-07 | INCY | 78.23 | 0.47 | 0.40 | 14988 |
| 2025-08-08 | INCY | 78.42 | 0.47 | 0.09 | 15052 |
| 2025-08-11 | INCY | 79.19 | 0.46 | 0.63 | 15302 |
| 2025-08-12 | INCY | 81.64 | 0.46 | 0.02 | 15387 |
| 2025-08-13 | INCY | 85.85 | 0.45 | 1.82 | 15532 |
| 2025-08-14 | INCY | 86.16 | 0.59 | 1.24 | 17418 |
| 2025-08-15 | INCY | 86.94 | 0.61 | 0.16 | 17811 |
| 2025-08-18 | INCY | 84.92 | 0.69 | 0.18 | 15979 |
| 2025-08-19 | INCY | 85.49 | 0.68 | 0.07 | 16241 |
| 2025-08-20 | INCY | 86.18 | 0.66 | 0.02 | 16428 |
| 2025-08-21 | INCY | 86.55 | 0.65 | 0.05 | 16737 |
| 2025-08-22 | INCY | 85.05 | 0.65 | 0.11 | 16722 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-28 | INCY | 70.16 | 181.0 | 962.0 | 5.83 |
| 2025-07-29 | INCY | 77.38 | 181.0 | 1122.3 | 5.83 |
| 2025-07-30 | INCY | 77.55 | 181.0 | 967.9 | 5.83 |
| 2025-07-31 | INCY | 74.89 | 53.4 | -36.9 | 6.18 |
| 2025-08-01 | INCY | 75.59 | 53.4 | 103.8 | 6.18 |
| 2025-08-04 | INCY | 78.04 | 56.2 | 140.9 | 6.23 |
| 2025-08-05 | INCY | 77.72 | 56.2 | 82.1 | 6.23 |
| 2025-08-06 | INCY | 77.68 | 56.2 | 87.6 | 6.08 |
| 2025-08-07 | INCY | 78.20 | 56.2 | 100.1 | 6.08 |
| 2025-08-08 | INCY | 78.39 | 56.0 | 92.6 | 6.09 |
| 2025-08-11 | INCY | 79.21 | 56.0 | 105.4 | 6.09 |
| 2025-08-12 | INCY | 81.61 | 56.0 | 137.5 | 6.09 |
| 2025-08-13 | INCY | 85.85 | 56.0 | 171.4 | 6.09 |
| 2025-08-14 | INCY | 86.16 | 56.0 | 94.4 | 6.09 |
| 2025-08-15 | INCY | 86.93 | 56.0 | 102.7 | 6.09 |
| 2025-08-18 | INCY | 84.93 | 56.0 | 52.6 | 6.09 |
| 2025-08-19 | INCY | 85.46 | 56.0 | 98.7 | 6.09 |
| 2025-08-20 | INCY | 86.18 | 56.0 | 102.0 | 6.09 |
| 2025-08-21 | INCY | 86.55 | 56.0 | 95.1 | 6.09 |
| 2025-08-22 | INCY | 85.04 | 56.0 | 61.6 | 6.09 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-28 | INCY | -3.08 | 6.04 | 3.73 |
| 2025-07-29 | INCY | -3.08 | 6.04 | 3.73 |
| 2025-07-30 | INCY | -3.08 | 6.04 | 3.73 |
| 2025-07-31 | INCY | -3.08 | 6.04 | 3.73 |
| 2025-08-01 | INCY | -3.05 | 6.04 | 3.70 |
| 2025-08-04 | INCY | -3.05 | 5.53 | 3.70 |
| 2025-08-05 | INCY | -3.05 | 5.53 | 3.70 |
| 2025-08-06 | INCY | -3.07 | 5.53 | 3.70 |
| 2025-08-07 | INCY | -3.07 | 5.53 | 3.70 |
| 2025-08-08 | INCY | -3.07 | 5.53 | 3.70 |
| 2025-08-11 | INCY | -3.07 | 5.57 | 3.70 |
| 2025-08-12 | INCY | -3.07 | 5.57 | 3.86 |
| 2025-08-13 | INCY | -3.07 | 5.57 | 3.86 |
| 2025-08-14 | INCY | -3.07 | 5.57 | 3.86 |
| 2025-08-15 | INCY | -3.07 | 5.57 | 3.86 |
| 2025-08-18 | INCY | -3.07 | 4.56 | 3.86 |
| 2025-08-19 | INCY | -3.08 | 4.56 | 3.85 |
| 2025-08-20 | INCY | -3.58 | 4.56 | 3.85 |
| 2025-08-21 | INCY | -3.58 | 4.56 | 3.85 |
| 2025-08-22 | INCY | -3.58 | 4.56 | 3.85 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.31
Avg. EPS Est. Current Quarter
1.67
Avg. EPS Est. Next Quarter
1.81
Insider Transactions
-3.58
Institutional Transactions
4.56
Beta
0.74
Average Sales Estimate Current Quarter
1254
Average Sales Estimate Next Quarter
1315
Fair Value
93.54
Quality Score
100
Growth Score
90
Sentiment Score
88
Actual DrawDown %
16.2
Max Drawdown 5-Year %
-49.1
Target Price
82.4
P/E
19.33
Forward P/E
11.96
PEG
0.2
P/S
3.62
P/B
3.96
P/Free Cash Flow
17.33
EPS
4.4
Average EPS Est. Cur. Y
6.09
EPS Next Y. (Est.)
7.16
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
18.99
Relative Volume
0.79
Return on Equity vs Sector %
-3.8
Return on Equity vs Industry %
9.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.32
EBIT Estimation
61.6
Incyte CorporationSector: Healthcare
Industry: Biotechnology
Employees: 2617
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
stock quote shares INCY – Incyte Corporation Stock Price stock today
news today INCY – Incyte Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch INCY – Incyte Corporation yahoo finance google finance
stock history INCY – Incyte Corporation invest stock market
stock prices INCY premarket after hours
ticker INCY fair value insiders trading